Sponsored message
Audience-funded nonprofit news
radio tower icon laist logo
Next Up:
0:00
0:00
Subscribe
  • Listen Now Playing Listen
Take Two

Using hallucinogens to treat anxiety from a serious illness diagnosis

In this April 13, 2010 photo, Dr. Stephen Ross shows an example of the pill a patient would take in a study on the effects of hallucinogenic drugs on the emotional and psychological state of cancer patients in New York. The pill could could either contain a placebo or psilocybin, the psychoactive ingredient in hallucinogenic mushrooms. (AP Photo/Seth Wenig)
In this April 13, 2010 photo, Dr. Stephen Ross shows an example of the pill a patient would take in a study on the effects of hallucinogenic drugs on the emotional and psychological state of cancer patients in New York. The pill could could either contain a placebo or psilocybin, the psychoactive ingredient in hallucinogenic mushrooms. (AP Photo/Seth Wenig)
(
Seth Wenig/AP
)

Take Two translates the day’s headlines for Southern California, making sense of the news and cultural events that affect our lives. Produced by Southern California Public Radio and broadcast from October 2012 – June 2021. Hosted by A Martinez.

Get LA News Updates Daily

We brief you on what you need to know about L.A. today.
Listen 5:12
Using hallucinogens to treat anxiety from a serious illness diagnosis

This is Part Four of our Psychedelic Science series. Click here for Part One, here for Part Two, and here for Part Three.

Psilocybin is the active ingredient that puts the magic in "magic mushrooms." And new research suggests it has tremendous potential as a treatment for severe anxiety caused by a serious illness or terminal diagnosis, according to researchers in the field. 

But look up psilocybin on the Drug Enforcement Agency's (DEA) website, and you’ll find this natural hallucinogen classified as a "Schedule One" drug. In government speak that means one that's dangerous and "without any accepted medical value."

But patients who have taken psilocybin as part of anxiety studies tell a different story. 

KPCC's Stephanie O'Neill reports.